US-based healthcare firm Abbott has completed the acquisition of medical device company Topera for $250m.

Topera develops electrophysiology technologies to improve the diagnosis and treatment of atrial fibrillation (AF), one of the most common heart rhythm disorders worldwide.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

With this acquisition, Abbott enters the $3bn catheter-based electrophysiology market that has grown annually at double-digit rates.

Abbott medical devices executive vice-president John Capek said: “The Topera acquisition gives Abbott a foundational entry in the large, high-growth electrophysiology market with breakthrough technologies that can transform how physicians treat people with complex heart rhythm disorders.

“Topera develops electrophysiology technologies to improve the diagnosis and treatment of atrial fibrillation (AF), one of the most common heart rhythm disorders worldwide.”

“The ability to more accurately target the areas of the heart perpetuating atrial fibrillation is a significant advancement in the field of electrophysiology and can transform patient care.”

A new diagnostic catheter and mapping software or rotor identification system developed by Topera allows physicians to identify target patient-specific rotors shown to be the sustaining mechanism for atrial fibrillation.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The rotor system features RhythmView workstation and FIRMap diagnostic catheter, which helps physicians identify and locate rotors, the specific areas within the heart acting as a sustaining mechanism for AF.

RhythmView workstation and FIRMap diagnostic catheter obtained US Food and Drug Administration (FDA) and CE Mark approval in 2013.

Abbott also secured the right to buy Advanced Cardiac Therapeutics (ACT), in a separate transaction. ACT is involved in developing an ablation catheter designed to improve the safety and effectiveness of ablation procedures.